Corbus Pharmaceuticals Holdings, Inc. CRBP
Set alert
4.22 USD 0.00 0.00%
At close · Oct 30
4.22 0.00 0.00%
After hours · Oct 30, 7:30 PM ET
3.95 Day range 4.31
3.99 52-week range 16.44
- YTD
- -48.16%
- 1 year
- -74.33%
- Open
- 4.20
- Prev close
- 4.22
- Mkt cap
- 81.62M
- Vol
- 2.32M
- Avg vol
- 900.31K
- EPS
- -6.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.95
- High
- 4.31
- Forward P/E
- -2.51
- Beta
- 2.56
- Short ratio
- 8.28
- Inst. own
- 105.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 16.87
- 200-d avg
- 37.65
- 1y target
- 56.78
2Y chart
Events in this range
- Nov 7, 2024Earnings: -1.15; estimate -0.99; surprise -16.16%
- Dec 2, 2024Rating: Piper Sandler · — → Overweight
Signals (106)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| RSI: Overbought | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 16, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| RSI: Overbought | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 8 months ago |
| SMA: Bearish | Jan 28, 2026 | 9 months ago |
| SMA: Bullish | Jan 27, 2026 | 9 months ago |
| RSI: Oversold | Jan 2, 2026 | 10 months ago |
| RSI: Oversold | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| RSI: Oversold | Dec 16, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 5, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Oct 31, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 24, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 17, 2025 | 1 year ago |
| RSI: Overbought | Sep 17, 2025 | 1 year ago |
| SMA: Bullish | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bearish | Aug 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 27, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 15, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jul 3, 2025 | 1 year ago |
| SMA: Bullish | Jul 2, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| RSI: Overbought | Jun 6, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| RSI: Overbought | Apr 24, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 20, 2025 | 1 year ago |
| RSI: Oversold | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 6, 2025 | 1 year ago |
| RSI: Oversold | Mar 4, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 14, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| RSI: Oversold | Jan 29, 2025 | 1 year ago |
| RSI: Oversold | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 24, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 20, 2024 | 1 year ago |
Key statistics
- Market cap
- 160.28M
- Enterprise value
- 2.58M
- Trailing P/E
- 0.00
- Forward P/E
- -2.51
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.06
- EPS (TTM)
- -4.71
- Beta
- 2.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -25.40M
- Total cash
- 159.36M
- Total debt
- 3.61M
- Return on equity
- -51.32%
- Shares outstanding
- 12.18M
- Short % of float
- 24.72%
- 50-day average
- 16.87
- 200-day average
- 37.65
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 56.78 +1245.4% upside
Now 4.22
- Target (low)
- 35.00
- Target (mean)
- 56.78
- Target (high)
- 75.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.26.
Financials — quick view
CRBP Revenue — quarterly 0
CRBP Net income — quarterly -35.04M
CRBP EPS — quarterly -1.81
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.99 | -1.15 | -0.16 | -16.16% |
| Aug 6, 2024 | Jun 1, 2024 | -1.16 | -0.90 | +0.26 | +22.41% |
| May 7, 2024 | Mar 1, 2024 | -1.09 | -0.83 | +0.26 | +23.85% |
| Mar 12, 2024 | Dec 1, 2023 | -2.36 | -1.81 | +0.55 | +23.31% |
| Nov 7, 2023 | Sep 1, 2023 | -2.06 | -2.27 | -0.21 | -10.19% |
| Aug 8, 2023 | Jun 1, 2023 | -3.10 | -2.05 | +1.05 | +33.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Piper Sandler | init | — | Overweight |
| Aug 7, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 7, 2024 | Oppenheimer | main | Outperform | Outperform |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jun 26, 2024 | B. Riley Securities | init | — | Buy |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- corbuspharma.com
News
Your note
Sign in to keep a note on CRBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTMEYER ANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
| CATLIN AVERY W | Director | Stock Award(Grant) | May 29, 2024 | 4,350 |
| COHEN YUVAL | Chief Executive Officer | Sale | Jun 17, 2024 | 77,221 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 19, 2024 | 0 |
| HOLMER ALAN F | Director | Conversion of Exercise of derivative security | Jun 13, 2024 | 5,829 |
| JACQUES RACHELLE SUZANNE | Director | Stock Award(Grant) | May 29, 2024 | 2,783 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 19.50% | 2,375,000 | 31.25M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 9.15% | 1,115,000 | 14.67M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 7.49% | 912,552 | 12.01M | Sep 29, 2024 |
| Blackrock Inc. | 6.59% | 802,721 | 10.56M | Sep 29, 2024 |
| Vanguard Group Inc | 5.30% | 645,650 | 8.50M | Sep 29, 2024 |
| Tang Capital Management, LLC | 4.93% | 600,000 | 7.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.21% | 391,276 | 5.15M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.70% | 329,220 | 4.33M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 269,243 | 3.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 169,055 | 2.22M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.85% | 104,055 | 1.37M | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 68,254 | 898.22K | Oct 30, 2024 |